{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "marketState": "REGULAR", "regularMarketChange": 0.025000095, "regularMarketTime": 1683872571, "regularMarketDayHigh": 2.505, "regularMarketDayRange": "2.505 - 2.505", "regularMarketDayLow": 2.505, "regularMarketVolume": 243, "regularMarketPreviousClose": 2.48, "bid": 2.45, "ask": 2.51, "fullExchangeName": "Frankfurt", "financialCurrency": "SEK", "regularMarketOpen": 2.505, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.20500016, "fiftyTwoWeekLowChangePercent": 0.089130506, "fiftyTwoWeekRange": "2.3 - 4.745", "fiftyTwoWeekHighChange": -2.2399998, "fiftyTwoWeekHighChangePercent": -0.47207582, "fiftyTwoWeekLow": 2.3, "fiftyTwoWeekHigh": 4.745, "exchange": "FRA", "shortName": "BIOINVENT INTERN.  SK 2", "longName": "BioInvent International AB (publ)", "messageBoardId": "finmb_139682", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 1.0080683, "regularMarketPrice": 2.505, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.06, "sharesOutstanding": 65804400, "fiftyDayAverage": 2.4919, "fiftyDayAverageChange": 0.013100147, "fiftyDayAverageChangePercent": 0.005257092, "twoHundredDayAverage": 3.28455, "twoHundredDayAverageChange": -0.77954984, "twoHundredDayAverageChangePercent": -0.23733841, "marketCap": 168729792, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 992930400000, "priceHint": 4, "symbol": "BIX0.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "The Gamma Building", "address2": "Ideongatan 1", "city": "Lund", "zip": "223 70", "country": "Sweden", "phone": "46 4 62 86 85 50", "website": "https://www.bioinvent.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.", "fullTimeEmployees": 102, "companyOfficers": [{"maxAge": 1, "name": "Dr. Martin  Welschof Ph.D.", "age": 61, "title": "Pres & CEO", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Stefan  Ericsson M.B.A.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Marie  Moores M.Sc., R.G.N.", "title": "Chief Operating Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kristoffer Rudenholm Hansson", "age": 48, "title": "Sr. VP of Technical Operations", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Bj\u00f6rn  Frend\u00e9us", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1973, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Cecilia  Hofvander", "age": 55, "title": "Sr. Director of Investor Relations", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Andres  McAllister", "age": 66, "title": "Chief Medical Officer", "yearBorn": 1956, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ingrid  Teige", "title": "Head of Preclinical Research", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sylvie  Ryckebusch", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 2, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 5, "governanceEpochDate": 1682899200, "maxAge": 86400}}], "error": null}}